Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine. 1993

R Kumar, and L I Wiebe, and E E Knaus
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.

A new class of 5-(1-azido-2-haloethyl)-2'-deoxyuridines 3a-c was synthesized by the regiospecific addition of XN3 (X = I, Br, Cl) to the vinyl substituent of 5-vinyl-2'-deoxyuridine. Treatment of the 5-(1-azido-2-iodoethyl) compound (3a) with H2 and 10% Pd/C yielded the 5-(1-azidoethyl) (4) and 5-(1-aminoethyl) (5) derivatives of 2'-deoxyuridine. A similar hydrogenation of 5-(1-methoxy-2-iodoethyl)-2'-deoxyuridine (1f) afforded the 5-(1-methoxyethyl) analog 6. The 5-(1-azido-2-haloethyl)-2'-deoxyuridines 3a-c exhibited in vitro antiviral activity against HSV-1, HSV-2, VZV, and EBV, but they were inactive against HCMV. In this group of compounds, the activity order was Cl > or = I > Br against HSV-1 and Br > or = Cl > I against HSV-2. A halogen atom in the 5-(1-azido-2-haloethyl) moiety 3a-c is an essential requirement since the 5-(1-azidoethyl) analog 4 was inactive, except for weak antiviral activity against VZV. Although the 5-(1-aminoethyl)-2'-deoxyuridine.HI (5) was inactive against HSV-1 and HSV-2, the 5-(1-methoxyethyl) compound 6 was equiactive to 5-ethyl-2'-deoxyuridine (EDU) against both HSV-1 and HSV-2 and 7-fold and 12-fold less active against HCMV relative to EDU and ganciclovir, respectively. All compounds investigated (3-6) exhibited low host cell cytotoxicity (IC50 > 118 microM) and inhibited cell proliferation only at high concentrations (IC50 > 76 microM).

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003587 Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS. Herpesvirus 5, Human,Human Herpesvirus 5,Salivary Gland Viruses,HHV 5,Herpesvirus 5 (beta), Human,Cytomegaloviruses,Salivary Gland Virus,Virus, Salivary Gland,Viruses, Salivary Gland
D003857 Deoxyuridine 2'-Deoxyuridine. An antimetabolite that is converted to deoxyuridine triphosphate during DNA synthesis. Laboratory suppression of deoxyuridine is used to diagnose megaloblastic anemias due to vitamin B12 and folate deficiencies. (beta 1-(2-Deoxyribopyranosyl))thymidine
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001386 Azides Organic or inorganic compounds that contain the -N3 group. Azide
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

R Kumar, and L I Wiebe, and E E Knaus
November 2001, Journal of medicinal chemistry,
R Kumar, and L I Wiebe, and E E Knaus
November 1965, Il Farmaco; edizione scientifica,
R Kumar, and L I Wiebe, and E E Knaus
February 2002, Bioorganic & medicinal chemistry letters,
R Kumar, and L I Wiebe, and E E Knaus
April 1981, Journal of medicinal chemistry,
R Kumar, and L I Wiebe, and E E Knaus
March 1993, Journal of medicinal chemistry,
R Kumar, and L I Wiebe, and E E Knaus
January 2002, Bioorganicheskaia khimiia,
R Kumar, and L I Wiebe, and E E Knaus
January 2005, Bioorganicheskaia khimiia,
R Kumar, and L I Wiebe, and E E Knaus
July 2010, Nucleosides, nucleotides & nucleic acids,
R Kumar, and L I Wiebe, and E E Knaus
June 1998, Nucleosides & nucleotides,
Copied contents to your clipboard!